Catheter developer Boston Scientific of Natick, MA, announced this month the signing of an agreement to purchase Schneider Worldwide, a division of Pfizer's Medical Technology Group, for $2.1 billion in cash, pending regulatory approvals. Schneider
Catheter developer Boston Scientific of Natick, MA, announced this month the signing of an agreement to purchase Schneider Worldwide, a division of Pfizer's Medical Technology Group, for $2.1 billion in cash, pending regulatory approvals. Schneider Worldwide operates out of Bulach, Switzerland, and manufactures stents and angioplasty devices and accessories. Last year the division claimed sales of $330 million. The deal should close later this year.
By acquiring Schneider, Boston Scientific will gain access to high-growth areas of interventional medicine, and will be able to offer a broader range of products, including rapid exchange catheters and nylon balloon technology. The deal reflects Boston Scientific's strategy of expanding its share in the interventional medicine market: Last year the company acquired Target Therapeutics of Fremont, CA, another catheter developer with a solid position in interventional neuroradiology.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.